Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNK_ASTER: SNK01 NK cells with gemcitabine/carboplatin ± cetuximab in TKI-failed NSCLC
KCT0006109Phase 2Recruiting
- Sponsor
- NKMax Co., Ltd.
- Start
- Jul 2021
- Modality
- Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of troculeucel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by NKMax Co., Ltd. Primary endpoints: Safety and tolerability of SNK01 in combination with chemotherapy ± cetuximab and Anti-tumor activity of SNK01 combination therapy. Started Jul 2021; status: recruiting.
02
Drugs
troculeucel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0006109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006109.